natgillin/translations-raw huggingface dataset:
-C3-5cycloalkyl; heteroaryl optionally substituted with one to two groups selected from: 
-C3-5cikloalkil; heteroaril opcijski supstituiran s jednom ili dvije skupine odabrane od sljedećih:
A compound of Formula la or a stereoisomer, tautomer, racemic, salt, hydrate, N-oxide form, or solvate thereof, Wherein 
Spoj Formule Ia, ili njegov stereoizomerni, tautomerni, racemični, solni, hidratni, N-oksidni oblik, ili njegov solvat,, naznačen time što
R2a is hydrogen, C4-6cycloalkyl or phenyl, said C4-6cycloalkyl and phenyl can optionally be substituted by 1, 2 or 3 substituents independently selected from the group consisting of: halogen, cyano, hydroxyl, carboxyl, amino, C1-4alkyl and haloC1-4alkyl; 
R* je vodik, Cagcikloalkil ili fenil, spomenuti Cagcikloalkil 1 fenil mogu izborno biti supstituirani s 1, 2 ili 3 supstituenta nezavisno odabranih iz skupine koja se sastoji od: halogena, cijano, hidroksila, karboksila, amino, Ci. aalkila i haloC,4alkila;
Fluid transmission coupling with independent member pressure relieving cam 
PRIJENOS TEKUĆINE SPOJEN S NEZAVISNIM ISPUSTOM ZA OLAKŠANJE PRITISKA
This is a tile with a central opening 11 and four zones 12, 13, 14, 15 sloping toward central opening 11. 
Keramička obložna pločica (12, 13, 14, 15; 22; 41; 50), koju se proizvodi postupkom koji se sastoji u koracima:
Such mineral mortar is also known in the art. 
Takva mineralna žbuka također je poznata u stanju tehnike.
a catalytic Fischer-Tropsch synthesis reaction unit. 
* katalitičku reakcijsku jedinicu za Fischer-Tropschovu sintezu.
a compound represented by the following formula: wherein ring A is 
Spoj predstavljen sljedećom formulom: iKem.
A syringe assembly 2 according to claim 1, wherein the engagement means 44 is disposed on an internal surface 42 of the outer sheath 6, preferably at least adjacent or towards the end 38 of the outer sheath 6, which is opposite to that from which medicament is dispensed, and/or wherein the engagement means 44 comprise screw threads. 
Set za špricu 2 prema zahtjevu 1, pri čemu se kopča 44 nalazi na vanjskoj površini 42 futrole 6, blizu ili uz onaj kraj 38 futrole 6, koji se nalazi nasuprot onome s kojeg se daje lijek, i/ili pri čemu kopča 44 sadrži navoje.
The kit of claims 16-20 wherein the nucleic acid probe(s) may contain within a longer sequence or comprise solely of the following sequences or a fragment thereof: 
Komplet u skladu s patentnim zahtjevima 16-20, naznačen time što jedna ili više nukleinskokiselinskih sondi mogu u sebi sadržavati dulji slijed ili se sastojati samo od sljedećih sljedova ili njihovih fragmenata:
The method of treating the disease or condition according to claim 16, wherein the psoriasis is one or more selected from the group consisting of chronic plaque psoriasis, guttate psoriasis, erythrodermic psoriasis, pustular psoriasis, inverse psoriasis, nail psoriasis, and psoriatic arthritis. 
Rafinirani ekstrakt namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što je psorijaza kronična pločasta psorijaza, kapljičasta psorijaza, eritrodermna psorijaza, pustozna psorijaza, inverzna psorijaza, psorijaza noktiju i/ili psorijatični artritis.
A process according to claim 1, wherein the effervescent composition of step i) is caused to solidify in a predetermined shape. 
Postupak prema zahtjevu 11 naznačen time da se pjenušavi materijal iz koraka i) skrućuje u predodređenom obliku.
According to a preferred embodiment of the present invention, R1 represents a hydrocarbon group comprising a straight chain, branched or cyclic group each containing up to 18 carbon atoms. 
R1 predstavlja ugljikovodičnu grupu koja sadrži ravnolančanu, razgranatu ili cikličnu grupu gdje svaka sadrži do 18 atoma ugljika, opcionalno gdje R1 predstavlja metil.
An emetic based on one or more constituents of radix ipecacuanha (ipecac root), preferably based on the constituent emetine may preferably be considered in the dosage form according to the invention, as are, for example, described in “Pharmazeutische Biologie—Drogen and ihre Inhaltsstoffe” by Prof. Dr. Hildebert Wagner, 2nd, revised edition, Gustav Fischer Verlag, Stuttgart, N.Y., 1982. 
U obliku davanja prema izumu u obzir može pogodno doći emetik na bazi jednog ili više sastojaka od korijena ipecacuanhae (korijen koji izaziva povraćanje), prvenstveno na bazi sastojka emetina, kako je na pr. opisano kod prof. dr. Hildebert Wagner u "Pharmazeutische Biologie-Drogen und ihre Inhaltsstoffe", prerađeno izdanje, naklada Gustav Fischer, Stuttgart, New York 1982.
A therapeutically effective amount of the pharmaceutical composition according to any of claims 1 to 8 for use in the treatment of a cancer in a patient. 
Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4 za uporabu u liječenju karcinoma ili za uporabu u proizvodnji cjepiva protiv karcinoma.
The present disclosure further relates to an in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is any peptide described. 
In vitro metoda za proizvodnju aktiviranih citotoksičnih T-limfocita (CTL) metoda je koja obuhvaća kontaktiranje in vitro CTL-a humanim MHC molekulama klase I s umetnutim antigenima koje se eksprimiraju na površini odgovarajuće stanice koja prezentira antigen u vremenskom razdoblju dovoljnom da se aktivira navedeni CTL na način svojstven antigenu, pri čemu je navedeni antigen peptid u skladu s patentnim zahtjevom 1 ili 2.
The pharmaceutical composition of Claim 6, wherein the pharmaceutical composition is in a solid dosage form. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 6, naznačen time što je farmaceutski pripravak u čvrstom obliku doziranja.
Accordingly, the sugar substitute should not only replace sugar but should additionally offer a wide range of health effects while providing the human body with the required amounts of fibres, vitamins and minerals. 
Slijedom toga, nadomjestak za šećer ne smije samo zamjenjivati šećer, već uz to mora iskazivati i širok raspon učinaka povoljnih za zdravlje, npr. da opskrbljuje ljudsko tijelo potrebnom količinom vlakana, vitamina i minerala.
A method of treating a mammal having a disease or medical condition mediated by treatment with a 5-HT4 receptor agonist, wherein the disease or medical condition is chronic constipation, constipation-predominant irritable bowel syndrome, functional dyspepsia, gastroparesis, gastroesophageal reflux disease, or drug-induced delayed transit, the method comprising administering to the mammal, a pharmaceutical composition comprising a pharmaceutically-acceptable carrier and a compound of formula (I): 
Uporaba iz Patentnog zahtjeva 17, naznačena time, da je medicinsko stanje poremećaj smanjene pokretljivosti gastrointestinalnog trakta. Uporaba iz Patentnog zahtjeva 17, naznačena time, daje medicinsko stanje odabrano iz skupine koju čine: sindrom iritabilnog crijeva, kronični zatvor, funkcionalna dispepsija, odgođeno pražnjenje želuca, gastroezofagalna refluksna bolest, gastropareza, postoperacijski ileus, intestinatna pseudoopstrukcija i usporeni tranzit crijevnog sadržaja uzrokovan lijekovima.
the anticancer platinum-coordinatedcomplex compounds are cisplatin, carboplatin, nedaplatin, and oxaliplatin; 
platinom-koordinirani kompleksni spojevi citostatici su cisplatin, karboplatin, nedaplatin, i oksaliplatin;
The antibody-drug-conjugate of claim 15, wherein said Ab is an antibody, or an antigen binding fragment thereof, and is selected from the group consisting of: 
Konjugat antitijela i lijeka iz patentnog zahtjeva 14, naznačeno time da rečeni Ab jest antitijelo, ili njegov fragment vezan na antigen, te odabran od:
The breaking strength of the tablets was determined with the stated apparatus in accordance with the stated method. 
Prijelomna čvrstoća tableta izmjerena je prema navedenoj metodi pomoću navedene aparature.
Polyoxyethylene-sorbitan-fatty acid esters, also called polysorbates, for example mono- and tri-lauryl, palmityl, stearyl and oleyl esters of the type known and commercially available under the trademark TWEEN. 
2) Estere polioksietilen-sorbitan-masne kiseline, također nazvane polisorbati, na primjer mono- i tri-lauril, palmitil, stearil 1 oleil esteri tog tipa su komercijalno raspoloživi pod zaštićenim nazivom TWEEN.
A method as claimed in claim 7, comprising the additional step of: filtering the clarified fraction withdrawn from said container (20), the filtration of said clarified fraction occurring at a higher degree of filtration than the filtration of said slurry (3). 
Postupak u skladu sa zahtjevom 7, naznačen time, da obuhvaća dodatni sljedeći korak: c3) filtriranje izbistrene frakcije izvađene iz navedenog spremnika (20), pri čemu se filtriranje odvija na višem stupnju filtracije nego filtriranje navedenog mulja (3).
A method for producing at least one IL-23p19 antibody, comprising translating the nucleic acid molecule according to claim 9 under conditions in vitro, in vivo or in situ, such that the IL-23p19 antibody is expressed in detectable or recoverable amounts. 
Postupak za proizvodnju najmanje jednog IL-23p19 protutijela, naznačen time što se sastoji od translacije molekule nukleinske kiseline prema zahtjevu 6 1li zahtjevu 7 pod uvjetima in vitro, in vivo ili in situ, tako da se IL-23p19 protutijelo eksprimira u količinama koje se mogu izmjeriti ili regenerirati.
about 5% sucrose; about 0.2% polysorbate 20; and 
(iv) polisorbat 20 u koncentraciji od oko 0,2 %; 1
is a pyridin-2-yl or pyrazin-2-yl group which is substituted by 2 substituents and wherein one of the substttuents is located at the para position and one of the substituents is located, a the ortho position of the pyridin-2-yl or pyrazin-2-yl group relative to the amide linker and wherein the substituents are independently selected from the group, consisting of cyano, amino, fluoro, bromo, chloro, hydroxyl, oxo, methyl, fluoromethyl, difluoromethyl, trifluoromethyl, methoxy, fluoromethoxy, difluoromethoxy and trifluromethoxy; 
je piridin-2-il-skupina ili pirazin-2-il-skupina, koja je supstituirana s dva supstituenta i pri čemu je jedan od supstituenata smješten na para-poziciji i jedan od supstituenata je smješten na orto-poziciji od piridin-2-il-skupine ili pirazin-2-il-skupine, u odnosu na amidnu poveznicu te su pritom supstituenti neovisno odabrani iz skupine koju čine: cijano, amino, fluoro, bromo, kloro, hidroksil, okso, metil, fluorometil, difluorometil, trifluorometil, metoksi, fluorometoksi, difluorometoksi i trifluorometoksi;
Such valves are used in many applications including, for example, for delivering accurate amounts of a drug to a patient or animal. 
Takovi ventili se upotrebljavaju u mnogim primjenama uključiv, na primjer, za isporuku točnih količina lijeka u pacijenta ili životinju.
In a further embodiment the invention also relates to use of a compound of the invention as the free base or a salt thereof for the preparation of a pharmaceutical composition for the treatment of social phobia. 
U jednom daljnjem obliku izum se također odnosi na korištenje spoja izuma kao slobodne baze ili njezine soli za pripravak farmaceutskog sastava kod za liječenje društvenih fobija.
More preferably, the water miscible organic solvent is at least one of acetone, methanol, ethanol, n-propanol, isopropanol, acetonitrile, methy-ethyl-ketone, or tetrahydrofuran. 
Poželjnije, organsko otapalo koje se miješa s vodom barem je jedno između acetona, metanola, etanola, n-propanola, isopropanola, acetonitrila, metil-etil-ketona.
The method of claim 1, wherein ammonia-containing off-gas of the finishing section is subjected to scrubbing to remove droplets and particles and subsequently to scrubbing with acidic scrubbing liquid in said off-gas treatment section. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time da se otpadni plin koji sadrži amonijak završnog dijela podvrgava pranju da se uklone kapljice i čestice, a potom i pročišćavanjem kiselom tekućinom za pročišćavanje u navedenom dijelu završne obrade.
a plurality of panels (2) having a shape such that they can be stacked on top of each other in a stacked state of the sectional door, and next to each other in a stored state of the sectional door; 
- mnoštvo ploča (2) koje imaju oblik tako da se mogu postavljati jedna na drugu u složenom stanju sekcijskih vrata, i jedna pored druge u pohranjenom stanju sekcijskih vrata;
a control unit comprising a microprocessor or microcontroller; 
- < kontrolnu jedinicu koja sadrži mikroprocesor ili mikrokontroler (41);
wherein the alkyl or cycloalkyl is unsubstituted or substituted with hydroxyl or amino; and wherein each R22 and R23 is independently selected from hydrogen and C1-6 alkyl, or R22 and R23 taken with the nitrogen to which they are attached are joined to form a 3 to 10 membered ring; 
pri čemu alkil ili cikloalkil je nesupstituiran ili supstituiran s hidroksilom ili amino; i svaki R22 i R23 su neovisno odabrani od vodika i C1-6alkila ili R22 i R23 mogu biti spojeni tako da tvore 3 do 10 člani prsten;
A method according to claim 2, further comprising: determining in the biological sample whether the serotonin transporter gene SLC6A4 of the test subject has the LL genotype of functional polymorphism serotonin transporter-linked polymorphic region 5-HTTLPR; wherein the presence of the LL genotype is an indication that the test subject will respond differently to treatment than a subject with the L/S or SS genotype; 
Metoda u skladu s patentnim zahtjevom 2, nadalje obuhvaća: određivanje u biološkom uzorku ima li gen za prijenosnik serotonina SLC6AA4 ispitanika LL genotip funkcionalnog polimorfizma polimorfne Tegije 5-HTTLPR povezane s prijenosnikom serotonina; pri čemu je prisustvo LL genotipa indikacija da će ispitanik drugačije odgovoriti na liječenje nego ispitanik s L/S ili
The antibody or antigen binding portion of any one of the preceding aspects, wherein the EGF-like ligand is selected from the group consisting of EGF, TGF-a, betacellulin, heparin-binding epidermal growth factor, amphiregulin and biregulin. 
Antitijelo ili njegov dio koji se vezuje za antigen u skladu s patentnim zahtjevom 5, naznačeno time što je ligand sličan s EGF odabran iz skupine koja se sastoji od EGF, TGF-a, betacelulina, heparin-vezujućeg epidermalnog faktora rasta, amfiregulina i biregulina.
A compound of formula (1c): 
Spoj naznačen time da ima formulu (1c): cI_ o
A pharmaceutical composition comprising a soluble mutant CTLA-4-Ig fusion protein of the invention and a pharmaceutically acceptable excipient or carrier (e.g., PBS) is prepared. 
(g) stanicu domaćina prema zahtjevu 11. Farmaceutski pripravak prema zahtjevu 12, naznačen time da sadrži farmaceutski prihvatljivu pomoćnu tvar ili farmaceutski prihvatljiv nosač i dimerni fuzijski protein prema zahtjevu 8.
The monoclonal antibody of item 7 which comprises VH and VL chains having sequences selected from one of the following groups of VH and VL sequences: 
Monoklonalno antitijelo iz patentnog zahtjeva 6 naznačeno time da sadrži Vu i VL lance koji imaju sekvencije odabrane iz jedne od sljedećih skupina Vg i Vr sekvencija:
An siRNA targeted to SEQ ID NO: 1 for use in the treatment of dry eye and/or ocular pain wherein the siRNA is administered at a dosage of from about 0.3 to about 0.9 mg per day. 
PATENTNI ZAHTJEVI 1. -siRNK usmjerena na SEK ID BR: 1 za primjenu u liječenju suhog oka i/ili boli u oku gdje je siRNK administrirana u dozi od oko 0.3 do oko 0.9 mg po danu.
V is heteroaryl being selected from the group of oxadiazolyl, triazolyl, pyrazolyl, pyrrolyl, furanyl, pyridyl, pyrimidyl and pyridazinyl, whereby V optionally is substituted by 1 to 4, preferably 1 or 2, more preferably 1 substituent independently of each other selected from the group of fluorine, chlorine, H3C-, tert- butyl-, F3C-, CH3O-, cyclobutyloxy-, N-morpholinyl, benzyl-O- and NC-, 
V je heteroaril odabran iz skupine koju čine: oksadiazolil, triazolil, pirazolil, pirolil, furanil, piridil, pirimidil i piridazinil, gdje je V po želji supstituiran s 1 do 4, poželjno s 1 ili 2, najbolje s jednim supstituentom međusobno neovisno odabranim/a iz skupine koju čine: fluor, klor, H3C-, tert-butil-, F3C-, CH3O-, ciklobutiloksi-, N-morfolinil, benzil-O-, i NC-, V je priključen na poziciji 2 od W, pri čemu pozicija i od W je priključna točka za W na skupinu CR2R3 u formuli (I);
According to the present invention, electronic circuit 4 is housed inside sunken seat 12 a, and is seated firmly inside the seat by means of a hardened silicone resin 40 embedding printed circuit 38 and electronic components 33 . 
U skladu s predmetnim izumom, elektronski krug 4 je smješten unutar upuštenog sjedišta 12a, i postavljen je čvrsto unutar sjedišta pomoću otvrdnute silikonske smole 40 u koju su ugrađeni štampani krug 38 i elektronske komponente 33.
The method of claims 1 to 5, wherein the (±)-A9-tetrahydrocannabinol comprises at least about 95% by weight, preferably at least about 98% by weight and more preferably at least about 99% by weight of trans-(-)-A9-tetrahydrocannabinol and trans-(+)-A9-tetrahydrocannabinol based on the total amount of cannabinoids. 
Postupak prema zahtjevima 1 do 5, naznačen time da (±)-A9-tetrahidrokanabinol sadrži najmanje oko 95% težinski, poželjno najmanje oko 98% težinski i još poželjnije najmanje oko 99% težinski trans-(-)-A9-tetrahidrokanabinola i trans-(+)-A9-tetrahidrokanabinola bazirano na ukupnoj količini kanabinoida.
The nucleic acid molecule of claim 1, wherein the nucleotide sequence has at least 95% identity to the sequence of SEQ ID NO. 
Molekula nukleinske kiseline prema patentnom zahtjevu 1, naznačena time, što je nukleotidna sekvenca najmanje 98 % ili 99 % identična sekvenci SEQ ID NO.
The bispecific antibody according to claim 19, wherein the disease is selected from the group consisting of: a TH2-mediated disease, an IL-4 and/or IL-13 mediated disease, an allergic disease, asthma, cancer, an autoimmune disease, a disease associated with abnormal production of IL-4 and/or IL-13, scleroderma and idiopathic pulmonary fibrosis. 
Bispecifično protutijelo ili fragment protutijela za uporabu prema zahtjevu 14, naznačeno time da je bolest odabrana iz skupine koju čine alergijska bolest, astma, rak, autoimuna bolest, sklerodermija i idiopatska plućna fibroza.
In patients given a standard therapy with metronidazole (for vaginal trichomoniasis or bacteriosis) or miconazole (for vaginal candidiasis), ascorbic acid given after the germ eradication was able to prevent fungal reinfection or superinfection in patients at risk. 
U pacijenata kojima je dana standardna terapija s metronidazolom (za vaginalnu trihomonijazu ili bakterijsku infekciju) ili mikonazol (za vaginalnu kandidijazu), askorbinska kiselina koja je primijenjena nakon iskorjenjivanja klica bila je sposobna spriječiti ponovnu gljivičnu infekciju ili superinfekciju u rizičnih pacijenata.
The compressor may include a plurality of compression cylinders. The BOG, which is compressed by the compressor and is transferred to the heat exchanger, may be compressed while passing through all or part of the plurality of compression cylinders included in the compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7, naznačen time što se BOG, koji se komprimira kompresorom (150;13), te prebaci u izmjenjivač topline (21), komprimira prilikom prolaska kroz sve ili dio od više kompresijskih cilindara (14) koje sadrži kompresor.
1-1962 or a food product comprising a Lactococcus lactis subsp. 
1-1962, ili prehrambeni proizvod koji sadrži bakteriju Lactococcus lactis subsp.
The reaction mixture is allowed to stir at room temperature for 4 hours and then the solvent is removed in vacuo. 
Reakcijsku smjesu se pusti miješati 4 sata pri sobnoj temperaturi i zatim se otapalo odstrani u vakuumu.
One LED illuminates when control signals are transmitted by the hand-held unit to the receiver, and also confirms the transmission of commands. 
Jedna LED dioda svijetli kad se odašilju kontrolni signali iz ručne jedinice prema prijemniku, te osim toga služi kao potvrda odašiljanja komandi.
In accordance with a first aspect of the present invention, there is provided a delayed release drug formulation for oral administration to deliver a drug to the colon of a subject, said formulation comprising a core and a coating for the core, the core comprising a drug and the coating comprising an outer layer and an inner layer, wherein the outer layer comprises a mixture of a first polymeric material which is susceptible to attack by colonic bacteria and a second polymeric material which has a pH threshold at about pH 5 or above, and wherein the inner layer comprises a third polymeric material that is soluble in intestinal fluid or gastrointestinal fluid, said third polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said third polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base. 
HR P20180965 T1 PATENTNI ZAHTJEVI Formulacija lijeka s produženim otpuštanjem za oralnu primjenu radi davanja lijeka u debelo crijevo pacijenta, pri čemu spomenuti pripravak sadrži: jezgro i prevlaku za jezgru, to jezgru koja sadrži lijek i ovojnicu koja sadrži vanjski sloj i unutarnji sloj; pri čemu vanjski sloj sadrži smjesu prvog polimernog materijala koji je osjetljiv na napad bakterija debelog crijeva i drugi polimerni materijal koji ima prag pH na pH 6 ili više, i pri čemu unutarnji sloj sadrži treći polimerni materijal koji je neionski polimer koji je topljiv u crijevnoj tekućini, ili gastrointestinalnoj tekućini, i najmanje jedan aditiv odabran iz puferskog sredstva i baze.
An aqueous pharmaceutical formulation, preferably with pH between 3.4 and 4.6, comprising zinc and insulin glargine for use in reducing the incidence of hypoglycaemia in the treatment of Type I and Type II Diabetes Mellitus in a patient with a long acting insulin, wherein the concentration of insulin glargine is 250-700 U/mL being equimolar to 250-700 IU human insulin. 
Vodena formulacija namijenjena upotrebi u skladu s patentnim zahtjevom 15, naznačena time što navedeni farmaceutski pripravak dodatno sadrži 0,1 ug do 10 ug liksisenatida po jedinici inzulin glargina. Vodeni farmaceutski pripravak koji sadrži inzulin glargin u koncentraciji od 300 jedinica po ml, što je ekvimolarno 300 ij. ljudskog inzulina, naznačen time što je namijenjen upotrebi u smanjivanju incidencije hipoglikemije u liječenju dijabetesa melitusa tip I i tip II kod pacijenta dugodjelujućim inzulinom.
Examples 13-15 The following compounds were prepared similarly to Example 12 from the approprite azide and H2/Pd:- 
Slijedeći spojevi napravljeni su na sličan način s Primjerom 2 iz odgovarajućeg azida i H2/Pd: -
The pharmaceutical composition for use according to claim 11, 12 or 13 wherein the patient is an individual with insufficient glycemic control despite monotherapy with a SGLT2 inhibitor, in particular the glucopyranosyl-substituted benzene derivative according to claim 1. 
18. Farmaceutski sastav za uporabu prema zahtjevu 11, 12 ili 13, naznačen time, da je pacijent pojedinac s nedovoljnom glikemijskom kontrolom usprkos monoterapiji sa SGLT2-inhibitorom, posebno s derivatom benzena 10
An expression vector capable of expressing a nucleic acid according to Claim 7 or 8. 
Vektor ekspresije sposoban za ekspresiju nukleinske kiseline prema Zahtjevu 4 ili 5.
The sheet (10) according to claim 7, characterized in that said metallic vapors are aluminum vapors. 
List (10) u skladu s patentnim zahtjevom 7, naznačen time, da su navedene metalne pare aluminijske pare.
The composition of claim 1, wherein the composition has at least 75%, at least 85%, or at least 95% fewer a2,6-linked sialic acid moieties than wild type SAP isolated from human serum. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time, da pripravak ima barem 75%, barem 85% ili barem 95% manje 02,6-vezanih ostataka sialne kiseline od divljeg tipa SAP izoliranog iz humanog seruma.